الرابط هنا

 A Swedish company specializing in the development of treatments against Alzheimer's has announced that it has recruited the first patient in its phase 1b clinical study aimed at testing a first vaccine against the disease. A potential vaccine Alzinova AB, a Swedish biopharmaceutical company, will soon offer its first Phase 1b clinical trial for an Alzheimer's disease vaccine called ALZ-101. The researchers have just recruited their first patient. A total of twenty-six patients will be included in the study. Participants will receive four doses of ALZ-101 or a placebo. The study looked at two different strengths of ALZ-101 for about 20 weeks. The first data is expected in the second half of 2023. The vaccine contains antibodies that the researchers say will directly target neurotoxic β-amyloid oligomers. The joint presence of β-amyloid aggregates and tau proteins are indeed the characteristic signs of Alzheimer's disease. Together, these two conditions gradually promote neu...